Search results for "Donor"

showing 10 items of 436 documents

Microvesicle Formation Induced by Oxidative Stress in Human Erythrocytes

2020

Extracellular vesicles (EVs) released by different cell types play an important role in many physiological and pathophysiological processes. In physiological conditions, red blood cell (RBC)-derived EVs compose 4&ndash

0301 basic medicinePhysiologyClinical BiochemistryCell<i>tert-</i>Bytyl hydroperoxide t-BOOHmedicine.disease_causeBiochemistryband 3ArticleFlow cytometry03 medical and health sciences0302 clinical medicinecalcium ionophore A23187medicineoxidative stressViability assay<i>tert</i>-Bytyl hydroperoxide t-BOOHnitric oxide donorMolecular BiologyBand 3Hemichromemicroparticlesbiologymedicine.diagnostic_testChemistryMicrovesiclelcsh:RM1-950Cell Biologytert-Bytyl hydroperoxide t-BOOHvesiculationRed blood cell030104 developmental biologymedicine.anatomical_structurelcsh:Therapeutics. Pharmacology030220 oncology & carcinogenesisphysiologybiology.proteinBiophysicserythrocytesOxidative stressAntioxidants
researchProduct

Inorganic nitrite and nitrate in cardiovascular therapy: A better alternative to organic nitrates as nitric oxide donors?

2017

In 1867 the organic nitrite, amyl nitrite, was introduced as a therapeutic agent in the treatment of angina pectoris and was later substituted by the organic nitrate nitroglycerin (NTG). Despite having a highly potent vasodilator capacity in veins>coronary arteries>arterioles, the vasodilator effects NTG are rapidly attenuated by the development of nitrate tolerance. We and others established that NTG treatment stimulates the production of reactive oxygen species such as superoxide and peroxynitrite with subsequent marked attenuation of the NTG vasodilator potency. The nitrite anion (NO2-) has more recently been characterized to possess novel pharmacotherapeutic actions such as modulation o…

0301 basic medicinePhysiologyVasodilator AgentsVasodilation030204 cardiovascular system & hematologyPharmacologyNitric OxideCardiovascular SystemNitric oxideAngina03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNitratemedicineAnimalsHumansNitric Oxide DonorsNitriteNitritesPharmacologyNitratesSuperoxidemedicine.diseaseVasodilation030104 developmental biologychemistryBiochemistryCardiovascular DiseasesMolecular MedicineAmyl nitritePeroxynitriteSignal Transductionmedicine.drugVascular Pharmacology
researchProduct

Does Pasteurized Donor Human Milk Efficiently Protect Preterm Infants Against Oxidative Stress?

2019

International audience; Pasteurized donor human milk (DHM) is the preferred alternative for infant nutrition when own mother's milk (OMM) is unavailable. Whether DHM is an efficient means for protecting preterm infants from oxidative stress remains unknown. We quantified a panel of oxidative stress biomarkers in urine samples from preterm infants (≤32 weeks of gestation and a birth weight ≤1500 g) receiving ≥80% of feeding volume as either DHM or OMM. The noninvasive in vivo assessment of oxidative stress showed no statistically significant difference between both groups at the time when full enteral nutrition (150 mL/kg body weight) was achieved and until hospital discharge. In addition, t…

0301 basic medicinePhysiology[SDV]Life Sciences [q-bio]Clinical BiochemistryPasteurizationmedicine.disease_causeBiochemistrylaw.inventionpreterm infant03 medical and health sciencesEnteral Nutritionfluids and secretionslawHumansMedicineoxidative stressLongitudinal StudiesProspective StudiesFood scienceMolecular BiologyGeneral Environmental Science2. Zero hungerMilk Human030102 biochemistry & molecular biologyfull enteral feedingbusiness.industryInfant Newbornfood and beveragesbiomarkersInfant nutritionCell BiologyInfant Low Birth Weight3. Good health030104 developmental biologydonor human milk (DHM)own mother's milk (OMM)PasteurizationGeneral Earth and Planetary SciencesFemalebusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionInfant PrematureOxidative stress
researchProduct

Mitochondrial DNA Replacement Techniques to Prevent Human Mitochondrial Diseases.

2021

Background: Mitochondrial DNA (mtDNA) diseases are a group of maternally inherited genetic disorders caused by a lack of energy production. Currently, mtDNA diseases have a poor prognosis and no known cure. The chance to have unaffected offspring with a genetic link is important for the affected families, and mitochondrial replacement techniques (MRTs) allow them to do so. MRTs consist of transferring the nuclear DNA from an oocyte with pathogenic mtDNA to an enucleated donor oocyte without pathogenic mtDNA. This paper aims to determine the efficacy, associated risks, and main ethical and legal issues related to MRTs. Methods: A bibliographic review was performed on the MEDLINE and Web of S…

0301 basic medicinePoor prognosisLegal positionMitochondrial DNAFarmacologiaWeb of scienceMEDLINEReviewmitochondrial DNABioinformaticsDNA MitochondrialCatalysisMitocondrisInorganic Chemistrylcsh:Chemistry03 medical and health sciencesmitochondrial donation0302 clinical medicineMedicineHumansPhysical and Theoretical ChemistryMolecular Biologylcsh:QH301-705.5Spectroscopymitochondrial diseases030219 obstetrics & reproductive medicinebusiness.industryOrganic ChemistryDonor oocyteGeneral MedicineDNAGenetic TherapyComputer Science ApplicationsNuclear DNAMitochondriaClinical trial030104 developmental biologylcsh:Biology (General)lcsh:QD1-999Oocytesmitochondrial replacementthree-parent babybusinessInternational journal of molecular sciences
researchProduct

Itinéraire d’un agent double

2016

Protein S-nitrosylation is now recognized as a ubiquitous regulatory mechanism. Like any post-translational modifications, S-nitrosylation is critical for the control of numerous cellular processes. It is now clear that S-nitrosylation is playing a double game, enhancing or inhibiting the tumor growth or the induction of cell death. Thanks to research aimed at demonstrating NO cytotoxic effects, new therapeutic strategies based on NO donor drugs have emerged. Although therapeutic NO donors can target a large number of proteins, the cellular mechanism is still not fully understood. This review reflects the current state of knowledge on S-nitrosylated proteins that take part of the oncogenic …

0301 basic medicineProgrammed cell deathMechanism (biology)Cell growthGeneral MedicineBiologyGeneral Biochemistry Genetics and Molecular Biology3. Good healthNo donorsCellular mechanism03 medical and health sciences030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesisCytotoxic T cellTumor growthSignal transductionNeurosciencemédecine/sciences
researchProduct

The Italian law on body donation: A position paper of the Italian College of Anatomists

2021

In Italy, recent legislation (Law No. 10/2020) has tuned regulations concerning the donation of one's postmortem body and tissues for study, training, and scientific research purposes. This study discusses several specific issues to optimise the applicability and effectiveness of such an important, novel regulatory setting. Some of these unsolved issues may involve the grantees of teaching and training activities, the role of academic anatomical institutes, the role of family members in the donation process, the universal time limit indicated for any donation, the handling of corpses, and the limited body donation and its subordination to the donation of organs and tissues. Critical issues …

0301 basic medicineStudents MedicalTissue and Organ ProcurementeducationTissue DonorLegislationBody donation programme Law Regulation Cadaver lab EducationCadaver labNOEducation03 medical and health sciencesBody donationAnatomistBody donation programme Law Regulation Cadaver lab EducationPolitical scienceMedicalCadaverHumansAnatomistsStudentsImplementationSettore BIO/16Body donation programmeSettore BIO/16 - Anatomia UmanaGeneral MedicineTissue DonorsTransplantationSubordination (finance)030104 developmental biologyItalyLawDonationBody donation programme; Cadaver lab; Education; Law; Regulation; Cadaver; Humans; Italy; Tissue Donors; Anatomists; Students Medical; Tissue and Organ ProcurementBody donation programme; Cadaver lab; Education; Law; RegulationPosition paperBody donation programme; Law; Regulation; Cadaver lab; Education030101 anatomy & morphologyAnatomyInefficiencyLawDevelopmental BiologyHumanRegulation
researchProduct

Recession Coverage Using Soft Tissue Substitutes

2018

Today, a variety of surgical procedures can be used to successfully treat gingival recession defects. Among them, the autogenous connective tissue graft in conjunction with a coronally advanced flap is commonly considered the gold standard procedure. However, the most significant disadvantages of this procedure are the potential morbidity associated with autogenous tissue harvesting and the limited availability of donor tissue. For these reasons, alternative surgical procedures using membranes, enamel matrix derivative, and soft tissue graft substitutes have been proposed and tested. The aim of the present chapter is to provide an overview on the use of soft tissue substitutes as a possible…

0301 basic medicinebusiness.industryDonor tissueDentistryConnective tissueSoft tissue030206 dentistrySurgical proceduresSoft tissue graft03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureTissue HarvestingEnamel matrix derivativeMedicinemedicine.symptombusinessGingival recession
researchProduct

Cytoprotective Effects of Dinitrosyl Iron Complexes on Viability of Human Fibroblasts and Cardiomyocytes

2019

Nitric oxide (NO) is an important signaling molecule that plays a key role in maintaining vascular homeostasis. Dinitrosyl iron complexes (DNICs) generating NO are widely used to treat cardiovascular diseases. However, the involvement of DNICs in the metabolic processes of the cell, their protective properties in doxorubicin-induced toxicity remain to be clarified. Here, we found that novel class of mononuclear DNICs with functional sulfur-containing ligands enhanced the cell viability of human lung fibroblasts and rat cardiomyocytes. Moreover, DNICs demonstrated remarkable protection against doxorubicin-induced toxicity in fibroblasts and in rat cardiomyocytes (H9c2 cells). Data revealed t…

0301 basic medicinedonors nitric oxideCellOxidative phosphorylationdinitrosyl iron complexesheart diseaseMitochondrionNitric oxide03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicinePharmacology (medical)Viability assayInner mitochondrial membranecell viabilityOriginal Researchchemistry.chemical_classificationPharmacologyReactive oxygen specieslcsh:RM1-950GlutathioneCell biology030104 developmental biologymedicine.anatomical_structurelcsh:Therapeutics. Pharmacologychemistry030220 oncology & carcinogenesismembrane potentialFrontiers in Pharmacology
researchProduct

Harnessing Unconventional T Cells for Immunotherapy of Tuberculosis

2020

Even if the incidence of tuberculosis (TB) has been decreasing over the last years, the number of patients with TB is increasing worldwide. The emergence of multidrug-resistant and extensively drug-resistant TB is making control of TB more difficult. Mycobacterium bovis bacillus Calmette–Guérin vaccine fails to prevent pulmonary TB in adults, and there is an urgent need for a vaccine that is also effective in patients with human immunodeficiency virus (HIV) coinfection. Therefore, TB control may benefit on novel therapeutic options beyond antimicrobial treatment. Host-directed immunotherapies could offer therapeutic strategies for patients with drug-resistant TB or with HIV and TB coinfecti…

0301 basic medicinelcsh:Immunologic diseases. AllergyTuberculosismedicine.medical_treatmentT cellImmunologyCD1HIV InfectionsMajor histocompatibility complexMucosal-Associated Invariant T Cellshost-directed therapy03 medical and health sciences0302 clinical medicineMHC class ImedicineImmunology and AllergyHumansTuberculosis Pulmonarybiologybusiness.industryImmunotherapyMycobacterium tuberculosisDonor Lymphocytesmedicine.diseaseAdoptive Transfer030104 developmental biologymedicine.anatomical_structuretuberculosisImmunologybiology.proteinCoinfectionBCG VaccineHIV-1cytotoxicityT cell receptorbusinesslcsh:RC581-607unconventional T cells030215 immunologyFrontiers in Immunology
researchProduct

Protein kinase inhibitor-based cancer therapies: Considering the potential of nitric oxide (NO) to improve cancer treatment.

2020

The deregulation of a wide variety of protein kinases is associated with cancer cell initiation and tumor progression. Owing to their indispensable function in signaling pathways driving malignant cell features, protein kinases constitute major therapeutic targets in cancer. Over the past two decades, intense efforts in drug development have been dedicated to this field. The development of protein kinase inhibitors (PKIs) have been a real breakthrough in targeted cancer therapy. Despite obvious successes across patients with different types of cancer, the development of PKI resistance still prevails. Combination therapies are part of a comprehensive approach to address the problem of drug r…

0301 basic medicinemedicine.drug_class[SDV]Life Sciences [q-bio]Nitric OxideBiochemistry03 medical and health sciences0302 clinical medicineNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansNitric Oxide DonorsMolecular Targeted TherapyProtein kinase AProtein Kinase InhibitorsPharmacologybusiness.industryKinaseCancerProtein kinase inhibitormedicine.disease3. Good health030104 developmental biologyDrug developmentTumor progressionDrug Resistance Neoplasm030220 oncology & carcinogenesisCancer cellCancer researchSignal transductionbusinessProtein KinasesSignal TransductionBiochemical pharmacology
researchProduct